Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia

This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.

Inclusion Criteria:

• Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder
• Body weight of 100-250 lbs
• Male or females
• 18-55 years of age

Exclusion Criteria:

• Subjects who are acutely psychotic
• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide